In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com

Start date: November 30, 2021

Chronic myeloid leukemia (CML) accounts for approximately 15% of adult leukemias. The treatment landscape of CML was transformed in 2001 with the approval of imatinib, the first BCR-ABL tyrosine kinase inhibitor (TKI) to be used in the management of this disease, and there are now 5 TKIs approved for the treatment of chronic-phase CML. Overall, the 5-year survival rate for all patients with CML has more than tripled, up from 22% in the mid-1970s to nearly 70% at present.

Oncology Best Practice™ is a nationwide series of live, regional activities held in locations across the United States that are deemed to have the highest educational need. This educational series will focus on practical challenges facing clinicians who treat patients with CML, including individualizing TKI selection, monitoring patients for response to therapy, treating patients who have a suboptimal response in the second-line setting, sequencing available therapies most effectively, and managing adverse effects associated with TKI therapy. This activity will use a variety of teaching modalities, including didactic presentation of current data, clinical case scenarios to illustrate application of data to practice, and discussions about how to address common clinical challenges.

• Review the most up-to-date evidence supporting treatment options for resistant CML
• Gain insights into how experts manage challenging cases of resistant CML
• Hear expert perspectives on how to individualize and optimize sequencing of available agents
• Learn how to manage TKI-associated adverse effects and nonadherence

This educational activity is directed toward academic and community-based hematologists, oncologists, pathologists, histologists, nurse practitioners, pharmacists, physician assistants, and other health care professionals involved in the treatment of patients with CML.

Upon completion of this activity, participants will be able to:

• Discuss efficacy and safety evidence concerning the application of TKI therapies in the management of patients with relapsed/refractory (R/R) CML
• Evaluate results from clinical trials conducted among patients with CML that assess the effectiveness of TKIs and methods to stratify risk for resistance in the context of therapeutic switching
• Determine effective strategies to ensure TKI adherence via proactive risk stratification for toxicities and management of treatment-associated toxicities
• Integrate approaches that allow practitioners to demonstrate confidence on practical methods to personalize care and optimize the application of TKI treatment strategies

This CME program is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Physicians’ Education Resource (PER) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity will be made available for 1.0 AMA PRA Category 1.0 Credits.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hours